Ireland
Every company in the roster headquartered in Ireland.
Every company in the roster headquartered in Ireland.
8 of 8 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Jazz PharmaceuticalsJAZZ · Nasdaq | 8 assets: 7 approved, 1 Ph 3 | Cannabidiol (JZP926)Phase 2/3 · Epilepsy | 31 Dec 2026Zanidatamab · Phase 2 | $15.5B | $2.9BSep 2026 | Cash-flow positive | $829M |
GH ResearchGHRS · Nasdaq | 1 asset: 1 Ph 2 | Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signal | None on record | $1.1B | $246MDec 2025 | ~22.6 qtrs | $39M |
Amarin CorporationAMRN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $236M | $323MSep 2026 | Cash-flow positive | $19M |
Alkermes plcALKS · Nasdaq | 6 assets: 5 approved, 1 Ph 3 | AlixorextonPhase 3 · Narcolepsy | Nov 2026Alixorexton · Phase 2 | — | $755MSep 2026 | Cash-flow positive | $430M |
Cosmo N.V.COPN · SIX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Keenova TherapeuticsPrivate | 4 assets: 4 approved | Approved assets only | None on record | — | $813MDec 2025 | Ended May 2026 | ~$177M |
Prothena Biosciences LimitedPRTA · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | PrasinezumabPhase 3 · Parkinson's Disease | 17 Dec 2026Moponetug · Phase 2 | — | $272MSep 2026 | ~9.6 qtrs | $83M |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.